Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Bre ...
Background Pericardium is considered electrically inert, but diffuse ST-elevation is an electrocardiographic marker of acute pericarditis. We hypothesised that ST-elevation in acute pericarditis may ...
Q4 2025 Earnings Call March 18, 2026 4:30 PM EDTCompany ParticipantsMaria Sainz - CEO, President & DirectorBrett Hale - ...
A powerful new real-world data platform could transform how scientists predict and understand Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD), reports a new study at Columbia ...
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC - an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit ...
Investor attention is turning to Tvardi Therapeutics as the biopharmaceutical company approaches several significant clinical data readouts in the first half of ...
Abstract: The exponential growth of data from sources such as social media, IoT, and enterprise systems has catalyzed a transformative shift in data management practices. This paper explores the ...
A new clinical classification scheme is presented, entitled “Acute Pulmonary Embolism Clinical Categories,” with 5 categories (A-E) and subcategories, ranging from low to high risk for adverse ...
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...
Presenting ten abstracts including observations on long-term safety, disease progression, and decline in muscle contractile area with givinostat Encore oral presentation also highlights analyses from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results